Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danegaptide in STEMI patients undergoing primary PCI
NCT01977755Phase 2Completed
- Sponsor
- Zealand Pharma
- Start
- Nov 2013
- Primary completion
- Dec 2015
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of danegaptide in ST elevation myocardial infarction (STEMI), sponsored by Zealand Pharma. Started Nov 2013; status: completed.
02
Drugs
danegaptide
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT01977755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01977755.